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Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We studied the
safety and efficacy of the combination of these drugs in patients with advanced cancer. In all, 50 patients were enrolled. Captopril was
given orally at a dose of 50mg bd daily. Fragmin was administered as a daily subcutaneous injection of 200unitskg
 1 for the first 28
days and 5000units thereafter. Marimastat was given at 10mg bd orally. Serum, plasma and urinary angiogenic factors were measured
at baseline and after 1 month of treatment. Inhibition of release of tumour necrosis factor alpha (TNF-alpha) from peripheral
lymphocytes was used as a surrogate pharmacodynamic end point. There was one case of haemorrhagic stroke and one upper
gastrointestinal haemorrhage. The commonest toxicity was myalgia. One of 10 patients with renal cancer had a partial response, and
three patients had a prolonged period of stable disease. The treatment significantly inhibited phytohaemagglutinin (PHA)-stimulated
TNF-alpha release from patient’s lymphocytes. The combination of marimastat, fragmin and captopril is well tolerated and has in vivo
activity. Inhibition of PHA-stimulated TNF-alpha release from lymphocytes is a surrogate pharmacodynamic marker of
metalloprotease inhibition.
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Tumour angiogenesis involves multiple signalling pathways that
provide potential therapeutic targets to inhibit tumour growth and
metastasis (Fox et al, 2001). Most trials of antiangiogenic agents to
date have used single agents. In an attempt to improve the efficacy
of angiogenic blockade, we describe a phase 2 clinical trial of a
combination of captopril, marimastat and low molecular weight
heparin, each of which has antiangiogenic activity in vitro and in
in vivo models. The aim was to assess the response to the
combination, including a predefined duration of stable disease
(SD), as angiogenic agents may have not necessarily caused
objective regression but still have effects on tumour growth. We
also planned to relate relevant mechanistic pathways before and
during therapy to assess whether early changes were related to
later anticancer effects. We also investigated whether inhibition of
release of tumour necrosis factor alpha (TNF-alpha) from
phytohaemagglutinin (PHA)-stimulated lymphocytes is a useful
surrogate pharmacodynamic marker for matrix metalloprotease
inhibition in patients treated with this drug combination.
Captopril, an angiotensin-converting enzyme (ACE) inhibitor,
has both antiangiogenic and antitumour activity in rodent models
(Volpert et al, 1996) and inhibits the growth of human renal
carcinoma xenografts (Hii et al, 1998). Epidemiological studies
suggest that the incidence of cancer and cancer deaths are lower in
hypertensive patients taking ACE inhibitors than in those treated
with other classes of antihypertensives (Lever et al, 1998). Captopril
has been shown to inhibit matrix metalloproteases 2 and 9, which
are involved in the angiogenic process (Prontera et al, 1999).
The rationale for the combination of captopril and the matrix
metalloprotease inhibitor (MMPI) marimastat in this study comes
from pre-clinical studies using the murine Lewis lung carcinoma
model (Prontera et al, 1999). When captopril was administered
with the MMPI Batimastat, the combination had synergistic activity
both in inhibition of matrix metalloproteases 2 and 9 in the tumour
cells and in blocking tumour growth and metastasis. Batimastat is
not suitable for oral administration, so the board spectrum orally
available MMPI, marimastat, is used in combination with captopril
(Wojtowicz-Praga et al, 1998; Macaulay et al, 1999).
As captopril and marimastat are synergistic inhibitors of
common target enzymes, we wanted to add a third antiangiogenic
agent that is not thought to work via MMP inhibition, in an
attempt to target multiple stages of the angiogenic pathway.
Low molecular weight heparins (LWMH) are antiangiogenic
in model systems, and prolong survival in animal models
(Folkman et al, 1983). Their mode of action is unclear but may
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linclude inhibition of proangiogenic factors such as fibroblast
growth factor 2 and angiogenin (Folkman, 1983; Norrby and
Ostergaard, 1996; Soncin et al, 1997). Low molecular weight
heparins have been shown to improve the survival of cancer
patients in retrospective analysis of randomised trials investiga-
ting the role of LWMH in treatment of deep vein thrombosis
(Green et al, 1992; Kakkar and Williamson, 1999; von Tempelhoff
et al, 2000).
Early-phase studies of antiangiogenic agents have been ham-
pered by the lack of pharmacodynamic end points to monitor the
effectiveness of therapy (Gelmon et al, 1999). A surrogate
pharmacodynamic marker for MMPI therapy is TNF-alpha
converting enzyme (TACE), which is inhibited by metallo-
protease inhibitors in preclinical studies (Gearing et al, 1994;
McGeehan et al, 1994). Both captopril and marimastat have
been shown to inhibit TNF-alpha release from stimulated
lymphocytes (Peeters et al, 1998). Marimastat acts so as to inhibit
TNF-alpha release from stimulated lymphocytes in a mouse model
(Tsuji et al, 2002). We assayed TNF-alpha release after PHA
treatment in blood samples (Thavasu et al, 1999; Propper et al,
2001), before, during and after treatment to see if we could observe
inhibition during MMPI treatment. In addition, the levels of
circulating and urinary angiogenic factors were measured to
determine if these varied with therapy and could be related to
response.
PATIENTS AND METHODS
Patients aged over 18 years with WHO performance status 0–2 and
histologically proven advanced malignancy refractory to conven-
tional treatment who gave written informed consent were eligible
for the trial. The trial was approved by the Oxford Research Ethics
Committee according to principles in the Helsinki Declaration.
Patients were required to have adequate haematological, renal and
hepatic function and have evaluable or measurable disease. The
exclusion criteria for the trial were a second malignancy,
pregnancy or lactation, pregnancy, inadequate contraception,
treatment with anti-cancer agents in the previous 4 weeks (6
weeks in the case of nitrosureas and mitomycin), serious systemic
illness and patients with contraindications to the study drugs.
Thus, patients with previous bleeding disorder, including heparin,
induced thrombocytopaenia, a history of gastrointestinal haemor-
rhage or uncontrolled peptic ulceration, renal artery stenosis,
cardiac outflow obstruction, severe arteriosclerosis, or recent
treatment with procainamide or allopurinol. Patients were not
allowed to receive aspirin, warfarin, lithium, allopurinol or
procainamide while on study.
The trial was carried out in two stages, expecting a lower
response for antiangiogenic therapy than conventional chemother-
apy. To detect the activity level of 10% including a SD of 4 months
or longer, Simon two-stage design (alpha¼0.05 and beta¼0.20%)
required enrolment of 18 patients to the first stage. If there were at
least three responders in the 18 evaluable patients, then an
additional 25 evaluable patients would be enrolled (total of 43
patients). To allow for patient dropouts or other reasons that
would declare a patient not evaluable, it was recommended that a
total of 50 patients be enrolled. As we developed the PHA assay,
and there was sufficient response in the first cohort, a subsequent
group of patients was recruited to prospectively analyse the effects
of the therapy on an in vivo pharmacodynamic end point and
relation to SD.
Drugs were administered according to the following schedule. A
test dose of 12.5mg of captopril was given orally. If patients
tolerated the first dose, then they continued on captopril taking
12.5mg twice daily for 1 week, followed by 25mg twice daily for 1
week, after which they took 50mg twice daily for the duration of
the study. Marimastat was administered orally at a dose of 10mg
twice daily for the duration of the study. This dose was chosen
based on pharmacokinetic data from a phase 1 trial of marimastat
in patients with advanced cancer, which suggested that this dose
would generate plasma concentrations in the range required to
inhibit the target enzymes, MMP2 and MMP9, while minimising
the incidence of musculoskeletal side effects (Wojtowicz-Praga
et al, 1998). This dose level has been used in several phase II and
III trials of marimastat as a single agent (Bramhall et al, 2002;
Miller et al, 2002; Shepherd et al, 2002). Fragmin was administered
by a once daily subcutaneous injection at a dose of 200unitskg
 1
for 4 weeks, after which the dose was reduced to 5000units per day
for the duration of the study. The dose of fragmin was reduced to
minimise both the risk of haemorrhage and severe bruising at
injection sites. In addition, prolonged administration of heparins
at high doses may result in osteoporosis in animal models
(Shaughnessy et al, 1995). Toxicities were graded according to the
NCI common toxicity criteria. Patients with grade 3 or 4 toxicity
were withdrawn from the study. Full details of dose reductions for
grade 1 or 2 toxicities are available from the authors. Briefly, for
grade 1 hypotension the dose of captopril was halved, for grade 2
hypotension captopril was omitted, but Fragmin and marimastat
continued. For myalgia grade 2, trial medication was discontinued
for 1 week and then restarted with half-dose marimastat if
symptoms had resolved or with marimastat omitted if symptoms
persisted.
Evaluation of the response to treatment was by appropriate
imaging after 16 weeks. Patients with SD or response were
permitted to remain on study until they developed unacceptable
toxicity or symptomatic disease progression. Complete response
(CR) was defined as the disappearance of all known disease,
determined by two observations not less than 4 weeks apart.
Partial response (PR) was a decrease of at least 50% of the sum of
the products of the largest perpendicular diameters of all
bidimensionally measurable lesions, as determined by two
observations not less than 4 weeks apart. It was not necessary
for all lesions to have regressed to qualify for PR, but no lesion
could have progressed and no new lesion appeared. SD was a
o50% decrease and o25% increase in the sum of the products of
the largest perpendicular diameters of all bidimensionally
measurable lesions, in the absence of any new lesions, lasting for
4 months or longer from start of therapy. Progressive disease (PD)
is a X25% increase in the size of at least one bidimensionally
measurable lesion or appearance of a new lesion. Tumour markers
were not used to assess response.
Assays of angiogenic factors
Samples of blood and urine were analysed for expression of
angiogenic factors at baseline and at 28 days using enzyme-linked
immunosorbent assays. Plasma levels of active plasminogen
activator inhibitor 1 (PAI-1) were assayed with an actibind-PAI-
1 kit (Tachnoclone, Dorking, UK). ELISA assays were obtained
from the following suppliers and used according to the manu-
facturer’s instructions: Human Endostatin Protein Accucyte Kit,
CN Biosciences, Nottingham, UK, soluble E selectin, basic
fibroblast growth factor, soluble Vascular cell adhesion molecule-
1 and vascular endothelial growth factor, R and D Systems,
Abingdon, UK, and von Willibrand factor, Alpha Labs, Hants, UK.
In total, 22 age- and sex-matched healthy controls, who were
taking no prescription medications and were free of neoplastic
disease, diabetes, cardiovascular or connective tissue disease,
supplied samples for controls. CD105, TGFb1 and CD105/TGFb1
complexes were determined by immunoassay as described, with
control samples taken from 40 healthy volunteers (Li et al, 2000).
Baseline samples were compared to on therapy results by
two-tailed paired t-tests, with a P-value o0.05 taken as signi-
ficant.
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lMeasurement of PHA-stimulated TNF-alpha release from
patient lymphocytes (whole blood cytokine assay)
Whole blood samples were collected into tubes containing
preservative-free heparin (30unitsml
 1 of blood) and PHA
(2mgml
 1 of blood, Murex Biotech Ltd, Dartford, UK) immedi-
ately pre-treatment and at 24h and 7 days after commencing
treatment. The assays were carried out as we previously described
(Thavasu et al, 1992).
The dose of captopril was increased after the TNF-alpha release
sample was taken. This is clarified in Figure 1, which summarises
the dose schedule. The 1-week sample reflects the level of dose
inhibition achieved by a captopril dose of 12.5mg twice daily in
combination with marimastat 10mg daily and fragmin 200uni-
tskg
 1.
Control samples were collected at the same time points into
tubes containing heparin alone. All samples were collected and
processed under sterile, pyrogen-free conditions and were
incubated at 371C in a 5% CO2 saturated humidified incubator.
After 24h of ex vivo stimulation with PHA, the blood samples were
cool spun and the plasma flash frozen at  201C.
Tumour necrosis factor alpha levels were measured using IRMA
kits (Biosource Europe, Brussels, Belgium). The TNF-alpha IRMA
range was from 15–500pgml
 1. The assay was calibrated with the
international reference preparation (87/650, National Institute of
Biological Standards and Controls, Potters Bar, Herts, UK) and was
used at detection limits of 20pgml
 1 plasma. The calibration,
standardisation and the assay format were specifically developed
for measuring TNF-alpha in plasma samples (Thavasu et al, 1999;
Propper et al, 2001).
RESULTS
Patients
A total of 50 patients were enrolled in the study. The
characteristics of the patients are shown in Table 1.
Toxicity
Two patients died while on study. A 28-year-old woman with
locally advanced cervical carcinoma refractory to radiotherapy and
chemotherapy developed profuse rectal bleeding, requiring a 6-
unit blood transfusion after 18 days on study. Study medication
was discontinued immediately. She had a normal prothrombin
time and activated partial thromboplastin time, but the haemor-
rhage continued and she died 6 days later. A second patient with
advanced transitional cell carcinoma of the renal pelvis and a
previous history of pulmonary emboli became non-specifically
unwell at home after 36 days on study. Trial medication was
stopped, but the next day she was admitted to a local hospital with
circulatory collapse and died shortly afterwards. A post mortem
was not carried out.
The principle toxicity of the treatment was major bleeding
events. In addition to the patient who died from uncontrolled
haemorrhage, one patient suffered a nonfatal haemorrhagic stroke
and another had an upper gastrointestinal haemorrhage, requiring
a 3-unit blood transfusion. Muscle and joint pains were common,
with grade 2 or 3 toxicity developing after mean of 69 days on
study in 46% patients (Table 2). Musculoskeletal side effects
responded to dose reduction or withdrawal of marimastat. In all,
21 patients (42%) required dose reduction of Marimastat. Mild
elevation of aspartate transaminase, taste changes and cough were
seen. Grade 2 hypotension occurred in two patients, but there was
no fall in blood pressure in any other patients.
Response to treatment
Response to treatment was evaluable in 45 patients. Of the five
nonevaluable patients, one withdrew from the study from personal
Captopril bd po
12.5 mg
25 mg
50 mg
02 4 8 Time
weeks
16
Fragmin od sc
200 units kg−1
5000 units
Marimastat bd po
10 mg bd
1
Figure 1 Dosage regimen for COMBAT study.
Table 1 Patient characteristics
Number of patients 50
Male 36
Female 14
Mean age (range), years 59.1 (27–80)
Diagnosis
Renal carcinoma 14
Prostate carcinoma 4
Colorectal carcinoma 10
Gastric carcinoma 4
Sarcoma 4
Breast carcinoma 2
Melanoma 2
Mesothelioma 2
Cervical carcinoma 2
Adrenal carcinoma 1
Parotid carcinoma 1
Small cell lung carcinoma 1
Bladder carcinoma 1
Carcinoma – unknown primary 2
WHO performance status
02 2
12 1
27
Table 2 Toxicity of captopril, marimastat and fragmin
Grade
Toxicity 0 1 2 3 4
Rectal bleeding 0 0 0 0 1
Haematemesis 0 0 0 0 1
CNS haemorrhage 0 0 0 0 1
Myalgia 8 20 16 7 0
Elevation of aspartate transaminase 26 18 5 1 0
Hypotension 35 14 2 0 0
Taste change 26 21 3 0 0
Cough 32 13 1 2 0
One patient died from haemorrhage and one patient died with circulatory collapse of
unknown cause.
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lpreference, two withdrew because of toxicity, and two died while
on trial treatment. One of the 10 patients with renal carcinoma had
a PR at 16 weeks, which was maintained for 503 days (Figure 2).
There were no other responses. Three patients with renal
carcinoma had SD at 16 weeks; the durations of disease
stabilisation for these patients were 204, 219 and 337 days. One
patient with colorectal carcinoma had radiological SD at 16 weeks
on a CT scan of the liver, but progressed clinically 7 days after the
scan. The remaining 40 evaluable patients had PD at or before 16
weeks.
Tumour necrosis factor alpha release from PHA-
stimulated lymphocytes
Tumour necrosis factor alpha release from PHA-stimulated
lymphocytes was measured ex vivo in samples of whole blood.
Blood samples, drawn at baseline and after 24h and 7 days on
study, were incubated at 371C in the presence or absence of PHA as
described in Materials and methods. There was no change in
lymphocyte counts between baseline and 7 days (mean (standard
deviation) 1.1 (0.5) at baseline and 1.2(0.5) at 7 days). Tumour
necrosis factor alpha production following 24h incubation with
PHA was assayed at baseline and at 24h and 7 days in 22 and 21
patients, respectively. Levels of TNF-alpha released were signifi-
cantly inhibited in the samples taken after 7 days of treatment, as
shown in Figure 3. The mean value of TNF-alpha post stimulation
at baseline was 170771041 (s.d.)pgml
 1, while at 7 days this had
fallen to 9077501pgml
 1, Po0.001 by two-tailed paired t-test.
Tumour necrosis factor alpha release from control samples
incubated in the absence of PHA was low in comparison to
samples treated with PHA and showed no change in TNF-alpha
levels with treatment (mean baseline control TNF-alpha release
26pgml
 1, mean day 7 control TNF-alpha release¼25pgml
 1).
There was no relationship between the baseline levels of TNF-alpha
release and the degree of inhibition produced by Marimastat.
Angiogenic markers
The descriptive statistics of assays of serum, plasma and urine for
proteins involved in angiogenesis are presented in Table 3. The
baseline values of soluble E selectin, endostatin, soluble VCAM,
Von Willibrand factor and plasminogen activator-1 were signifi-
cantly different from age- and sex-matched healthy controls (all
Po0.01). Intrapatient variability was small, but paired significance
tests revealed that there was a statistically significant rise in the
level of Von Willibrand factor and V-CAM and statistically
significant falls in the values of CD105, CD105/TGFb1 complex
and E Selectin. Though statistically significant, the magnitude of
these changes was small (see Table 3). Anti Xa assays were
significantly elevated at 1 and 2 months (3–10-fold), consistent
with the patients receiving Fragmin therapy.
We also analysed whether changes in the level of angiogenic
factors on treatment correlated with outcome (PR or SD vs PD).
The levels of TGFb1were significantly different after 2 months,
comparing the SDþPR and PD groups (median (range) SDþPR
41(0–202), PD 21 (0–166), P¼0.046). Endostatin levels were
higher in patients with PD at 2 months (median (range) SDþPR
11.7(4.9–27), PD 15.25 (3.2–45), P¼0.010). Finally, we examined
whether the baseline levels of angiogenic factors were predictive of
outcome. The baseline level of endostatin was higher in patients
who went on to have PD than in those who had SD or PR at
evaluation (median (range) PD¼15.3 (3.2–45), SDþPR¼11.7
(4.9–27) P¼0.027). In contrast, baseline levels of activated factor
VII were lower in patients who went on to progess (median (range)
PD¼68 (41–114), SDþPR¼80 (53–144), P¼0.01). Levels of
activated factor VII were not influenced by treatment. There were
no other significant differences for the markers assayed between
patients with PD or SDþPR.
DISCUSSION
This study is the first reported trial to evaluate a combination of
agents with antiangiogenic activity in model systems as opposed to
single agents. The synergy between matrix metalloprotease
inhibitors and captopril in vitro supports their use in combination
in this study. As Fragmin is thought to exert its antiangiogenic
effects by a different mechanism and is well tolerated in cancer
patients, we hoped that its inclusion would increase the efficacy of
the combination without increasing toxicity.
The trial medication was generally well tolerated. The side
effects are those predicted from the drugs used as single agents.
The musculoskeletal toxicity was dose limiting in a phase I
marimastat, though the plasma levels achieved at doses of 50mg
bd and above were substantially greater than those needed to
inhibit MMP function in vitro (Wojtowicz-Praga et al, 1998). The
dose of marimastat in this study, 10mg twice daily, was chosen to
decrease the likelihood of musculoskeletal side effects. The level of
musculoskeletal toxicity was substantially below that seen in the
phase I study of marimastat. Only seven patients (14%) developed
grade 3 symptoms, and these responded to dose reduction or
withdrawal of marimastat. The other common side effects were
Figure 2 Response to treatment in a patient with renal carcinoma. CT
sections imaging the right adrenal gland (arrowed) in a patient with renal
carcinoma. (A) Baseline scan, (B) scan after 16 weeks of treatment.
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ltaste change and cough, both of which are known side effects of
captopril (Havelka et al, 1982).
Serious toxicity was confined to haemorrhage. The three
major bleeding events seen were a rectal bleed from a tumour
mass, an upper gastrointestinal haemorrhage and a haemorrhagic
stroke. The first two events occurred while the patients were
on full dose, the latter on lower dose Fragmin. Cancer patients
receiving anticoagulation therapy have a substantially increased
risk of bleeding, of the order of 12% per year of treatment,
compared with patients with nonmalignant disease (Prandoni et al,
2002). In the only published randomised study comparing
prolonged LMWH treatment with conventional anticoagulation,
the risk of bleeding with 3 months of LMWH treatment was
lower than with warfarin therapy in patients with deep vein
thrombosis (Pini et al, 1994). However, it is possible that the
combination of Fragmin with marimastat and captopril may
increase the risk of serious haemorrhage in patients with advanced
cancer.
There was one PR to treatment in the trial in a patient with renal
carcinoma. This patient had to stop taking marimastat due to
musculoskeletal side effects. In addition, three of the total of 10
patients with renal carcinoma experienced prolonged disease
stabilisation. We conclude that trial medication may have some
activity in renal carcinoma. A randomised study is needed to
confirm if this is the case. There was no evidence of activity in the
other tumour types in the study.
The investigation of MMPIs and other biological therapies in
cancer would be greatly enhanced by pharmacodynamic assays to
confirm the efficacy of the drug in achieving its desired biological
target effect in early phase studies (Fox et al, 2001). Candidate
targets for MMPI activity are MMP2 and MMP9. However, in the
Phase I study of marimastat, there was no inhibition of the activity
plasma MMPs 2 and 9 in zymographic assays, despite achieving
marimastat concentrations above that required to inhibit these
enzymes in vitro (Wojtowicz-Praga et al, 1998). We therefore
looked for alternative markers of MMPI activity.
TNF levels after ex vivo PHA stimulation
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Figure 3 Tumour necrosis factor alpha release from patients’ lymphocytes stimulated ex vivo with PHA. Blood samples were taken from patients at
baseline, after 24h and 1 week of treatment, and incubated with phytohaemagglutinin for 24h prior to analysis for TNF-alpha release.
Table 3 Changes in levels of angiogenic factors during trial treatment
Angiogenic factor
Control
median (range) n 0 days median
28 days
median
56 days
median
P*( 0vs
28 days)
P*( 0vs
56 days)
Von Willibrand Factor (iudl
 1) 91 (34–153) 47 140 (94–212) 150 (77–215) 147 (108–222) NS 0.004
S oluble V-CAM (ngml
 1) 470 (170–860) 47 560 (320–1030) 610 (320–1210) 623 (320–1200) 0.009 0.01
Soluble E Selectin (ngml
 1) 38.5 (11–100) 47 58 (18–280) 50 (17–350) 49 (15–420) 0.0052 NS
Serum VEGF (pgml
 1) 77.5 (18–8000) 42 150 (10–195,000) 150 (15–270,000) ND NS ND
Plasma VEGF (pgml
 1) ND 42 95 (9–1,800,000) 110 (10–1,900,000) ND NS ND
Endostatin (ngml
 1) 7.75 (1.5–24) 47 14 (3.8–49) 15 (3.4–48) 13 (3.2 –45) NS NS
bFGF (pgml
 1) 2 (1.9) 47 2 (0.2–8) 2.1 (0.2–11.2) 2.25 (0.2–13) NS NS
Plasminogen activator inhibitor1 (unitsml
 1) 7 (1.8–22.6)) 47 11 (3.2–38.5) 10.8 (2.5–40) 12.8 (3.6–80) NS NS
CD105 (ngml
 1) 0.88 (0.07–25) 50 1.02 (0–15.7) 0.99 (0–3.8) 0.94 (0–25) 0.01 0.03
TGF b1 (pgml
 1) 41 (0–202) 50 25 (0–384) 27 (0–327) 28.5 (0–202) NS NS
CD105/TGF b1 complex (unitsml
 1) 0 (0–2.7) 50 0.6 (0–7) 0.5 (0–2.3) 0.4 (0–5.8) NS 0.007
Anti Xa (IUml
 1) ND 50 0.02 (0–0.1) 0.2 (0–0.83) 0.07 (0–0.5) o0.0001 o0.0001
Thrombin-antithrombin complex (mgl
 1) ND 49 1.69 (0.01–61) 2.27 (0.01–55) 1.61 (0.01–48) NS NS
Activated Factor VII (mUml
 1) ND 50 73.3 (41–144) 66.2 (22–149) 66.8 (32–178) NS NS
Thrombomodulin (ngml
 1) ND 50 3.25 (0.8–47) 3.19 (1–14) 3.01 (1–76) NS NS
ND¼not done; *¼values calculated by sign rank test; n¼number of patients assayed; NS¼not significant (P40.05).
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lWe assayed serum, urine and plasma levels of proteins involved
in angiogenesis. Although there were statistically significant
changes in the level of Von Willibrand factor, CD105, VCAM
and E Selectin during treatment, the magnitude of these effects was
small, and as with the other markers there was considerable inter
patient variation. The elevation of Von Willibrand factor and
VCAM could reflect endothelial damage and release of these
factors. The changes in CD105 and its complex with TGFb1, as well
as reduction in E selectin, are compatible with an inhibitory effect
on activated tumour endothelium. Likewise, while baseline levels
of endostatin and activated factor VII were significantly elevated
(P¼0.03 and 0.01, respectively) at 8 weeks in patients who
progressed compared with those with SD or PR, the differences
were small and the degree of inter-patient variation prevents the
use of endostatin and activated factor VII as predictive markers for
the trial therapy.
As an alternative, we evaluated the inhibition of TNF-alpha
release from PHA-stimulated lymphocytes, a process known to be
inhibited by matrix metalloprotease inhibitors. Significant inhibi-
tion of TNF-alpha release from PHA-stimulated lymphocytes was
seen by 24h on the study treatment, becoming more marked after
7 days. A fall in TNF-alpha release occurred in 21 of 25 patients
assayed. The degree of inhibition of TNF-alpha release varied
considerably in magnitude between patients, but this assay offers a
surrogate pharmacodynamic marker for this combination therapy
and possibly for other MMPIs.
In conclusion, we found that the combination of marimastat,
fragmin and captopril was generally well tolerated. Serious toxicity
in the form of major bleeding may be attributable to fragmin. The
combination may have activity in renal carcinoma, but confirma-
tion of this would require a randomised study. We found that the
measurement of levels of proteins involved in angiogenesis in the
serum, plasma or urine may provide some discrimination as a
pharmacodynamic marker to follow the combination therapy, but
that the ex vivo measurement of TNF-alpha release following PHA
stimulation of lymphocytes in whole blood samples may indicate
activity of the combination and is worthy of further study.
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